Indeed, the pathogen seems like ancient history — but as recent developments indicate, tuberculosis isn’t done with us yet.

There are multiple chapters near you. Select your preferred chapter.

Aurinia can still see growth in product revenues from Lupkynis and has a chance to show that AUR200 has some value in 2025.

For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ ...

In a rainforest of central Belize, a wildlife ranger saw an oddly colored animal fall out of a tree. The fleeting glimpse ...

All-Star Victor Wembanyama won’t be able to finish the rest of the NBA season due to deep vein thrombosis. What is this ...

The proof-of-concept study is one of the first to combine B and T cell analysis and potentially paves the way for tests that ...

The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...

Friday marks the 60th anniversary of the assassination of Malcolm X (also known as el-Hajj Malik el-Shabazz) following a ...

Roy Keane's daughter opened up on how the Manchester United legend helped her deal with an incurable disease which left her ...

However, a newer lupus drug, anifrolumab (brand name Saphnelo), has shown promising results in reducing organ damage, ...